MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Skiriute, Daina ^a   Vaitkiene, Paulina ^a   Saferis, Viktoras ^a   Asmoniene, Virginija ^a   Skauminas, Kestutis ^a   Deltuva, Vytenis P ^a   Tamasauskas, Arimantas ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

CASP8; CD81; DNA methylation; DR4; GATA6; Glioblastoma; MGMT; MSP; Survival

Indexed keywords

BISULFITE; CASPASE 8; CD81 ANTIGEN; DNA; HLA DR4 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR GATA 6;

ADULT; AGE DISTRIBUTION; ARTICLE; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CASP8 GENE; CD81 GENE; CONTROLLED STUDY; DNA METHYLATION; DR4 GENE; FEMALE; GATA6 GENE; GENE; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MONOTHERAPY; OPERATION DURATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PROMOTER REGION; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD81; CASPASE 8; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GATA6 TRANSCRIPTION FACTOR; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEINS;

EID: 84861792883     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-218     Document Type: Article

References (28)

1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003. 10.1056/NEJMoa043331, 15758010.
2. Laffaire J, Everhard S, Idbaih A, Criniere E, Marie Y, de Reynies A, Schiappa R, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Thillet J, Ducray F. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 2011, 13:8498.
3. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fern-Īndez A, Ropero S, Schackert G, Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009, 4:255-264.
4. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, . Cancer Genome Atlas Research Network Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010, 17:510-522. 10.1016/j.ccr.2010.03.017, 2872684, 20399149, Cancer Genome Atlas Research Network.
5. WHO Classification of tumours of the central nervous system 2007, IARC, Lyon, Louis DN, Ohgaki H, Wiestler OD, Cavenee WK.
6. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59:793-797.
7. Drucker L, Tohami T, Tartakover-Matalon Z, Shapiro H, Radnay J, Lishner M. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 2006, 27:197-204. 10.1093/carcin/bgi209, 16113057.
8. Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV. Hypermethylation of the GATA genes in lung cancer. Clin Cancer Res 2004, 10:7917-7924. 10.1158/1078-0432.CCR-04-1140, 15585625.
9. Lee KH, Lim SW, Kim HG, Kim DY, Ryu SY, Joo JK, Kim JC, Lee JH. Lack of death receptor 4 (DR4) expression through gene promoter methylation in gastric carcinoma. Langenbecks Arch Sur 2009, 394:661-670.
10. van Noesel MM, van Bezouw S, Salomons GS, Voute PA, Pieters R, Baylin SB, Herman JG, Versteeg R. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res 2002, 62:2157-2161.
11. Shureiqi I, Jiang W, Fischer SM, Xu X, Chen D, Lee JJ, Lotan R, Lippman SM. GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. Cancer Res 2002, 62:1178-1183.
12. Cecener G, Tunca B, Egeli U, Bekar A, Tezcan G, Erturk E, Bayram N, Tolunay S. The Promoter Hypermethylation Status of GATA6, MGMT, and FHIT in glioblastoma. Cell Mol Neurobiol 2012, 32:237-244. 10.1007/s10571-011-9753-7, 21928112.
13. Hervouet E, Vallette FM, Cartron PF. Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis 2010, 1:e8. 10.1038/cddis.2009.7, 3032516, 21364627.
14. Kamnasaran D, Qian B, Hawkins C, Stanford WL, Guha A. GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model. Proc Natl Acad Sci USA 2007, 104:8053-8058. 10.1073/pnas.0611669104, 1876570, 17463088.
15. Caslini C, Capo-chichi CD, Roland IH, Nicolas E, Yeung AT, Xu XX. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 2006, 25:5446-5461. 10.1038/sj.onc.1209533, 16607277.
16. Haveri H, Westerholm-Ormio M, Lindfors K, Maki M, Savilahti E, Andersson L, Heikinheimo M. Transcription factors GATA-4 and GATA-6 in normal and neoplastic human gastrointestinal mucosa. BMC Gastroenterol 2008, 8:9. 10.1186/1471-230X-8-9, 2323380, 18405344.
17. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rew Immunol 1998, 16:89-109.
18. Sadikovic B, Yoshimoto M, Chilton-Macneill, Thorner P, Squire JA, Zielenska M. Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Hum Mol Genet 2009, 18:1962-1975. 10.1093/hmg/ddp117, 19286668.
19. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC. Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene 2008, 27:490-498. 10.1038/sj.onc.1210655, 17653094.
20. Aguilera DG, Das CM, Sinnappah-Kang ND, Joyce C, Taylor PH, Wen S, Hasselblatt M, Paulus W, Fuller G, Wolff JE, Gopalakrishnan V. Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL. J Neurooncol 2009, 93:303-318. 10.1007/s11060-008-9788-x, 19148581.
21. Elias A, Siegelin MD, Steinmüller A, von Deimling A, Lass U, Korn B, Mueller W. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 2009, 15:5457-5465. 10.1158/1078-0432.CCR-09-1125, 19706813.
22. Martinez R, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 2007, 28:1264-1268. 10.1093/carcin/bgm014, 17272309.
23. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001, 20:5865-5877. 10.1038/sj.onc.1204750, 11593392.
24. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009, 27:5743-5750. 10.1200/JCO.2009.23.0805, 19805672.
25. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, Sharma MC, Sharma BS, Mahapatra AK, Suri A, Sarkar C. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011, 18:66-70. 10.1016/j.jocn.2010.04.050, 20888234.
26. Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, Quillien V, Mosser J. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 2011, 11:701.
27. Fulda S, Sieverts H, Friesen C, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997, 57:3823-3829.
28. Rehemtulla A, Hamilton CA, Chinnaiyan AM, Dixit VM. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). J Biol Chem 1997, 272:25783-25786. 10.1074/jbc.272.41.25783, 9325306.